BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34279688)

  • 1. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.
    Zhou C; Wang Y; Ma L; Qian X; Yang C; Zeng M
    Eur Radiol; 2022 Jan; 32(1):78-88. PubMed ID: 34279688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
    Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
    Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
    Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
    Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
    Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
    J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
    Sheng R; Yang C; Zhang Y; Wang H; Zheng B; Han J; Sun W; Zeng M
    Radiol Med; 2023 Sep; 128(9):1047-1060. PubMed ID: 37474663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathological components correlated with MRI features and prognosis in combined hepatocellular carcinoma-cholangiocarcinoma.
    Zhou C; Lu X; Wang Y; Qian X; Yang C; Zeng M
    Eur Radiol; 2022 Oct; 32(10):6702-6711. PubMed ID: 35976399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study.
    Zhang G; Chen BW; Yang XB; Wang HY; Yang X; Xie FC; Chen XQ; Yu LX; Shi J; Lu YY; Zhao HT
    World J Gastroenterol; 2022 Nov; 28(41):5968-5981. PubMed ID: 36405111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
    Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
    Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
    Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
    Xiao Y; Zheng X; Zhou C; Huang P; Wu F; Yang C; Zeng M
    Eur Radiol; 2023 Feb; 33(2):1412-1421. PubMed ID: 36112193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma based on preoperative contrast-enhanced CT and clinical data.
    Zhang J; Dong W; Li Y; Fu J; Jia N
    Eur J Radiol; 2023 Jun; 163():110839. PubMed ID: 37121101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
    Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
    Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative evaluation of MRI features and inflammatory biomarkers in predicting microvascular invasion of combined hepatocellular cholangiocarcinoma.
    Zhang J; Dong W; Liu W; Fu J; Liao T; Li Y; Huo L; Jia N
    Abdom Radiol (NY); 2024 Mar; 49(3):710-721. PubMed ID: 38112787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinicopathologic and MRI features of combined hepatocellular-cholangiocarcinoma in patients with or without cirrhosis.
    Yoon J; Hwang JA; Lee S; Lee JE; Ha SY; Park YN
    Liver Int; 2021 Jul; 41(7):1641-1651. PubMed ID: 33503328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?
    Zhou C; Huang P; Wu F; Xiao Y; Yang C; Zeng M
    Abdom Radiol (NY); 2024 Mar; ():. PubMed ID: 38427077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Imaging and Clinically Relevant Features of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Hepatocellular Carcinoma.
    Huang X; Li Y; Long L
    Med Sci Monit; 2019 Nov; 25():8595-8601. PubMed ID: 31726461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.
    Li R; Yang D; Tang CL; Cai P; Ma KS; Ding SY; Zhang XH; Guo DY; Yan XC
    BMC Cancer; 2016 Feb; 16():158. PubMed ID: 26917546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.